Octavian Therapeutics

What Octavian Therapeutics does

Octavian Therapeutics was a UK-based, privately-held drug discovery company founded in 2017 and headquartered in Oxford, focused on developing non-addictive pain medications that target the body's Endocannabinoid System (ECS). Its scientific premise was that compounds acting on ECS receptors could treat debilitating visceral and chronic pain without the addictive properties of opioid-based analgesics, addressing the opioid dependency crisis in pain management. The company's stated end users were patients with conditions such as Irritable Bowel Syndrome and other pain-related disorders.

The company's pipeline was built around proprietary derivatives, in-licensed compounds, and new chemical entities (NCEs) designed to engage the ECS. Its lead asset was OCT-461201, a CB2 receptor agonist in Phase I clinical trials for visceral pain associated with diarrhoea-predominant IBS (IBS-D). The team was positioned around deep pharmaceutical operating experience, with stated prior responsibility for over 20 regulatory approvals of new medicines in the US and EU across R&D, IP, legal, and finance functions.

Commercially, Octavian was a pre-revenue development-stage biotech with no disclosed products on market. The intended business model was to generate revenue through out-licensing, royalty agreements, or acquisition exit once clinical milestones were achieved. As of 2 May 2025, the company ceased trading and Nicola Baker of Rushtons Insolvency Limited was appointed Administrator, placing the entity in insolvency proceedings with all operations halted.

Name

Octavian Therapeutics

Legal name

Octavian

Website

https://octavianRx.com

Company type

Private

Founded year

2017

Operating status

Closed

Headcount range

11–50 employees

Short description

Octavian Therapeutics was a UK-based, pre-revenue drug discovery company developing non-addictive pain medications targeting the Endocannabinoid System, with lead asset OCT-461201 in Phase I trials for IBS-D visceral pain; the company ceased trading in May 2025.

Ownership category

akta.pro rank

Product category

Pharmaceutical Drug Development

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Gastroenterology Specialty Pharmaceuticals (HLAIACAE)

akta.pro secondary industries

Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI), Pain Relief & Anti-Inflammatory (Analgesics) (HLAIADAA)

Keywords

• Endocannabinoid drug discovery
• Pain therapeutics development
• Clinical stage pharmaceuticals
• CB2 receptor agonists
• Non-opioid pain medications

Headquarters

HQ city

Oxford

HQ country

United Kingdom

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Pharmaceutical Drug Development: Pre-revenue drug development company focused on developing endocannabinoid-based therapies. Revenue would come from drug commercialization, licensing, or acquisition upon successful clinical development.

Marketing channels2 records

Core offering

Octavian Therapeutics is a clinical-stage pharmaceutical drug discovery company developing a pipeline of proprietary, in-licensed, and new chemical entity compounds that target the Endocannabinoid System (ECS) to deliver non-addictive pain medications as alternatives to opioids. Its lead pipeline candidate, OCT-461201, is a CB2 receptor agonist in Phase I clinical trials for visceral pain associated with Irritable Bowel Syndrome (IBS-D). The company ceased trading in May 2025 and is under administration.

Product overview

Octavian Therapeutics is a pharmaceutical company pioneering endocannabinoid-based drug discovery. The company is developing a range of compounds including proprietary derivatives, in-licensed compounds, and new chemical entities (NCEs) targeting the Endocannabinoid System (ECS). Their portfolio includes OCT-461201 (a CB2 agonist in Phase I for visceral pain/IBS) alongside other pipeline candidates targeting conditions such as pain and oncology. The company ceased trading in May 2025 with an administrator appointed.

Differentiator

Problem solved

Functional benefit

Products and services

• OCT-461201

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators2 records

Recent moves3 records

Expansion highlights2 records

Direct peers

• Corbus Pharmaceuticals: Corbus developed Lenabasum (ajulemic acid), a cannabinoid-derived drug for inflammatory and fibrotic diseases. Closely aligned with Octavian's approach of developing novel ECS-targeting compounds for serious indications.
• InMed Pharmaceuticals: InMed develops cannabinoid-based pharmaceuticals leveraging proprietary biosynthesis platforms. Comparable as a small-cap clinical-stage cannabinoid therapeutics developer focused on rare diseases and pain.
• Botanix Pharmaceuticals: Botanix Pharmaceuticals develops synthetic cannabinoid therapeutics, with a lead dermatology program (Sofpironium Bromide). Comparable clinical-stage developer of cannabinoid-based prescription drug products.
• Tetra Bio-Pharma: Tetra Bio-Pharma develops prescription cannabinoid-based drugs for pain and oncology. Shares Octavian's dual focus on pain management and oncology via cannabinoid mechanisms.
• Ardelyx: Ardelyx markets Tenapanor (IBSRELA) for IBS-C and is developing additional GI therapies. Comparable as a specialty GI pharma targeting the same IBS patient population with a differentiated mechanism.
• GW Pharmaceuticals (Jazz Pharmaceuticals): Jazz Pharmaceuticals acquired GW Pharmaceuticals, the pioneer in cannabinoid-derived prescription medicines (Sativex, Epidiolex). Most directly comparable peer — both develop endocannabinoid/phytocannabinoid-based therapeutics for serious medical conditions, sharing the same underlying scientific platform.
• Zynerba Pharmaceuticals: Zynerba develops transdermal cannabinoid therapies for rare neurological conditions (Fragile X syndrome, etc.). Directly comparable clinical-stage cannabinoid pharma focused on pipeline development rather than plant cultivation.
• Ironwood Pharmaceuticals: Ironwood markets Linaclotide (Linzess) for IBS-C and has a focused GI pipeline. Directly relevant for the IBS market OCT-461201 targets, providing commercial-scale reference for the GI pain indication.

Broad incumbents

• Pfizer: Pfizer has a broad pain and gastroenterology portfolio and has historically acquired cannabinoid-adjacent assets. Relevant as a potential acquirer with the resources to advance a Phase I CB2 asset and the commercial reach to compete in the IBS pain market.
• Bristol Myers Squibb: BMS operates a large GI franchise (Celgene heritage with Zeposia) and has strategic interest in non-opioid pain. Relevant as a broad incumbent that could license or acquire ECS-targeting assets to expand its pain pipeline.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat2 records

Key risks6 records

Key highlights5 records

Customer concentration

• Xx.com/octavianrx
• LinkedInlinkedin.com/company/octavian-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Octavian Therapeutics